These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 25155989)
1. Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa. Cogan J; Weinstein J; Wang X; Hou Y; Martin S; South AP; Woodley DT; Chen M Mol Ther; 2014 Oct; 22(10):1741-52. PubMed ID: 25155989 [TBL] [Abstract][Full Text] [Related]
2. Intravenous gentamicin therapy induces functional type VII collagen in patients with recessive dystrophic epidermolysis bullosa: an open-label clinical trial. Woodley DT; Hao M; Kwong A; Levian B; Cogan J; Hou Y; Mosallaei D; Kleinman E; Zheng K; Chung C; Kim G; Peng D; Chen M Br J Dermatol; 2024 Jul; 191(2):267-274. PubMed ID: 38366625 [TBL] [Abstract][Full Text] [Related]
3. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients. Woodley DT; Cogan J; Hou Y; Lyu C; Marinkovich MP; Keene D; Chen M J Clin Invest; 2017 Aug; 127(8):3028-3038. PubMed ID: 28691931 [TBL] [Abstract][Full Text] [Related]
4. Novel readthrough agent suppresses nonsense mutations and restores functional type VII collagen and laminin 332 in epidermolysis bullosa. Levian B; Hou Y; Tang X; Bainvoll L; Zheng K; Badarinarayana V; Aghamohammadzadeh S; Chen M Mol Ther Nucleic Acids; 2024 Dec; 35(4):102334. PubMed ID: 39391765 [TBL] [Abstract][Full Text] [Related]
5. Amlexanox Enhances Premature Termination Codon Read-Through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis Bullosa. Atanasova VS; Jiang Q; Prisco M; Gruber C; Piñón Hofbauer J; Chen M; Has C; Bruckner-Tuderman L; McGrath JA; Uitto J; South AP J Invest Dermatol; 2017 Sep; 137(9):1842-1849. PubMed ID: 28549954 [TBL] [Abstract][Full Text] [Related]
6. Characterization of mutant type VII collagens underlying the inversa subtype of recessive dystrophic epidermolysis bullosa. Woodley DT; Cogan J; Mosallaei D; Yim K; Chen M J Dermatol Sci; 2021 Nov; 104(2):104-111. PubMed ID: 34674926 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa. Hong SA; Kim SE; Lee AY; Hwang GH; Kim JH; Iwata H; Kim SC; Bae S; Lee SE Mol Ther; 2022 Aug; 30(8):2664-2679. PubMed ID: 35690907 [TBL] [Abstract][Full Text] [Related]
8. Identification of novel small molecule-based strategies of COL7A1 upregulation and readthrough activity for the treatment of recessive dystrophic epidermolysis bullosa. Jover I; Ramos MC; Escámez MJ; Lozoya E; Tormo JR; de Prado-Verdún D; Mencía Á; Pont M; Puig C; Larraufie MH; Gutiérrez-Caballero C; Reyes F; Trincado JL; García-González V; Cerrato R; Andrés M; Crespo M; Vicente F; Godessart N; Genilloud O; Larcher F; Nueda A Sci Rep; 2024 Aug; 14(1):18969. PubMed ID: 39152155 [TBL] [Abstract][Full Text] [Related]
9. Collagen VII Expression Is Required in Both Keratinocytes and Fibroblasts for Anchoring Fibril Formation in Bilayer Engineered Skin Substitutes. Supp DM; Hahn JM; Combs KA; McFarland KL; Schwentker A; Boissy RE; Boyce ST; Powell HM; Lucky AW Cell Transplant; 2019; 28(9-10):1242-1256. PubMed ID: 31271052 [TBL] [Abstract][Full Text] [Related]
10. Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector. Jacków J; Titeux M; Portier S; Charbonnier S; Ganier C; Gaucher S; Hovnanian A J Invest Dermatol; 2016 Jul; 136(7):1346-1354. PubMed ID: 26994967 [TBL] [Abstract][Full Text] [Related]
12. Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa. Berthault C; Gaucher S; Gouin O; Schmitt A; Chen M; Woodley D; Titeux M; Hovnanian A; Izmiryan A J Invest Dermatol; 2024 Jun; 144(6):1322-1333.e13. PubMed ID: 38043638 [TBL] [Abstract][Full Text] [Related]
13. Does the position of the premature termination codon in COL7A1 correlate with the clinical severity in recessive dystrophic epidermolysis bullosa? Ishiko A; Masunaga T; Ota T; Nishikawa T Exp Dermatol; 2004 Apr; 13(4):229-33. PubMed ID: 15086338 [TBL] [Abstract][Full Text] [Related]
14. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Chen M; Kasahara N; Keene DR; Chan L; Hoeffler WK; Finlay D; Barcova M; Cannon PM; Mazurek C; Woodley DT Nat Genet; 2002 Dec; 32(4):670-5. PubMed ID: 12426566 [TBL] [Abstract][Full Text] [Related]
15. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. Gache Y; Baldeschi C; Del Rio M; Gagnoux-Palacios L; Larcher F; Lacour JP; Meneguzzi G Hum Gene Ther; 2004 Oct; 15(10):921-33. PubMed ID: 15585108 [TBL] [Abstract][Full Text] [Related]
16. Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa. Murauer EM; Gache Y; Gratz IK; Klausegger A; Muss W; Gruber C; Meneguzzi G; Hintner H; Bauer JW J Invest Dermatol; 2011 Jan; 131(1):74-83. PubMed ID: 20720561 [TBL] [Abstract][Full Text] [Related]